AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
NEWTON, Mass., March 07, 2018 -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Alexey Margolin, Ph.D., Allena’s Chief Executive Officer, will present a company overview and clinical and regulatory update at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 3:30 p.m. ET in Boston, MA.
A live audio webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. A replay of the webcast will be available on the Allena website for 30 days following the presentation.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]
